uniQure (QURE) Is Up 67.9% After FDA Backs AMT-130 Data For Accelerated Approval Path

Qure recently received positive FDA feedback that three-year data from its Phase I/II AMT-130 trial in Huntington’s disease can serve as the primary basis for an accelerated Biologics License ...

ClearPoint Neuro: AMT-130's FDA Reversal Revives The Bull Case

ClearPoint Neuro remains a speculative Buy, offering leveraged exposure to gene therapy commercialization and neurosurgery ...

uniQure Announces Plan for BLA Submission for AMT-130 in Huntington’s Disease

Phase I/II study can serve as the primary basis of a Biologics License Application for accelerated approval with FDA ...